Charles River Laboratories International (NYSE:CRL) Stock Breaks Below Fifty Day Moving Average - What's Next?

Charles River Laboratories International logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CRL fell below its 50-day moving average, trading as low as $310.52 versus the average of $316.09; shares were last reported at $314.29.
  • Analyst views were mostly positive: 12 rated the stock Buy, three Hold and one Sell, for a consensus “Moderate Buy” and average price target of $311.67.
  • The company beat quarterly earnings and revenue estimates, posting EPS of $3.09 against $2.97 expected and revenue of $982.73 million versus $960.36 million; revenue was down 2.2% year over year.
  • MarketBeat previews top five stocks to own in December.

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $316.09 and traded as low as $310.52. Charles River Laboratories International shares last traded at $314.2860, with a volume of 1,154,115 shares traded.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on CRL shares. Deutsche Bank increased their target price on shares of Charles River Laboratories International from $300.00 to $320.00 and gave the stock a "buy" rating in a research report on Friday, September 25th. Zacks Research downgraded shares of Charles River Laboratories International from a "strong-buy" rating to a "hold" rating in a research note on Monday, November 2nd. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $180.00 to $310.00 in a research report on Thursday, August 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of Charles River Laboratories International in a research report on Monday, September 28th. Finally, Jefferies Financial Group raised their target price on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the company a "buy" rating in a research note on Monday, September 28th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $311.67.

Check Out Our Latest Research Report on Charles River Laboratories International

Charles River Laboratories International Stock Down 4.2%

The firm has a 50-day moving average of $316.09 and a 200 day moving average of $231.19. The stock has a market capitalization of $15.06 billion, a price-to-earnings ratio of 345.37, a price-to-earnings-growth ratio of 3.03 and a beta of 1.36. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.76.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, beating the consensus estimate of $2.97 by $0.12. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. The business had revenue of $982.73 million during the quarter, compared to the consensus estimate of $960.36 million. During the same period in the prior year, the firm earned $2.43 earnings per share. The business's quarterly revenue was down 2.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current year.

Insider Transactions at Charles River Laboratories International

In related news, EVP Shannon M. Parisotto sold 2,156 shares of the stock in a transaction dated Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total value of $742,547.96. Following the completion of the transaction, the executive vice president owned 4,807 shares of the company's stock, valued at approximately $1,655,578.87. This represents a 30.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Foster sold 24,042 shares of the stock in a transaction dated Thursday, October 22nd. The shares were sold at an average price of $350.00, for a total value of $8,414,700.00. Following the completion of the transaction, the director directly owned 31,596 shares of the company's stock, valued at $11,058,600. This represents a 43.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 60,740 shares of company stock worth $19,528,128. Corporate insiders own 1.30% of the company's stock.

Hedge Funds Weigh In On Charles River Laboratories International

A number of institutional investors have recently made changes to their positions in the business. PCM Encore LLC acquired a new stake in shares of Charles River Laboratories International during the third quarter worth approximately $227,000. Advisors Asset Management Inc. acquired a new stake in Charles River Laboratories International in the third quarter valued at $613,000. Innovator Capital Management LLC acquired a new stake in Charles River Laboratories International in the third quarter valued at $781,000. Liontrust Investment Partners LLP bought a new position in Charles River Laboratories International during the 3rd quarter valued at $105,000. Finally, Integrated Wealth Concepts LLC boosted its stake in Charles River Laboratories International by 4.2% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 792 shares of the medical research company's stock valued at $234,000 after acquiring an additional 32 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

(Get Free Report)

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company's offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Charles River Laboratories International Right Now?

Before you consider Charles River Laboratories International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.

While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines